Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 6/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | LTB4R | Q15722 | 4/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.40 |
| ▸ | PPARD | Q03181 | 4/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3593830 | 0.88 | LTB4R (0.43) | PPARAPPARGLTB4RPTGDR2PPARD | |
| SCHEMBL3585113 | 0.87 | LTB4R (0.44) | PPARAPPARGLTB4RPPARDLTB4R2 | |
| SCHEMBL3586956 | 0.87 | KDM4E (0.44) | PPARAPPARGLTB4RPPARDNR1H2 | |
| SCHEMBL13441808 | 0.78 | PPARD (0.41) | PPARAPPARGPTGDR2PPARDTBXAS1 | |
| SCHEMBL3577648 | 0.77 | ALDH1A1 (0.42) | PPARGPTGDR2 | |
| SCHEMBL13637193 | 0.77 | PPARG (0.51) | PPARAPPARGLTB4RPPARDNR1H2 | |
| SCHEMBL3583333 | 0.76 | TBXAS1 (0.43) | PPARAPPARGLTB4RLTB4R2TBXAS1 | |
| SCHEMBL3589584 | 0.75 | PPARG (0.47) | PPARAPPARGLTB4RPTGDR2PPARD | |
| SCHEMBL13407823 | 0.74 | NPC1 (0.60) | PPARAPPARGLTB4RPPARDLTB4R2 | |
| SCHEMBL3576162 | 0.74 | LTB4R (0.48) | PPARAPPARGLTB4RPTGDR2PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622491-B2 | Type 2 diabetes, atherosclerosis, cardiovascular disease, Syndrome X; carboxylic acids with dialkyldiether or thioether linking groups e.g. {4-[3-(2-Benzotriazol-2-yl-4-chloro-phenoxy)-propoxy]-phenyl}-acetic acid and {4-[3-(2-benzotriazol-2-yl-4-thiophen-2-yl-phenoxy)-propoxy]-phenyl}-acetic acid | METABOLEX INC. (US) | 2009-11-24 | — | — | US | claimed |
| EP-1776111-A2 | MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | METABOLEX, INC. (US) | 2007-04-25 | — | — | EP | claimed |
| US-20060058301-A1 | Modulators of PPAR and methods of their preparation | METABOLEX, INC. (US) | 2006-03-16 | — | — | US | claimed |
| WO-2006020916-A2 | MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | METABOLEX, INC. (US) | 2006-02-23 | — | — | WO | claimed |
| US-20100087468-A1 | MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | METABOLEX, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087468-A1 | MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | METABOLEX, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087468-A1 | MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | METABOLEX, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-7622491-B2 | Type 2 diabetes, atherosclerosis, cardiovascular disease, Syndrome X; carboxylic acids with dialkyldiether or thioether linking groups e.g. {4-[3-(2-Benzotriazol-2-yl-4-chloro-phenoxy)-propoxy]-phenyl}-acetic acid and {4-[3-(2-benzotriazol-2-yl-4-thiophen-2-yl-phenoxy)-propoxy]-phenyl}-acetic acid | METABOLEX INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622491-B2 | Type 2 diabetes, atherosclerosis, cardiovascular disease, Syndrome X; carboxylic acids with dialkyldiether or thioether linking groups e.g. {4-[3-(2-Benzotriazol-2-yl-4-chloro-phenoxy)-propoxy]-phenyl}-acetic acid and {4-[3-(2-benzotriazol-2-yl-4-thiophen-2-yl-phenoxy)-propoxy]-phenyl}-acetic acid | METABOLEX INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622491-B2 | Type 2 diabetes, atherosclerosis, cardiovascular disease, Syndrome X; carboxylic acids with dialkyldiether or thioether linking groups e.g. {4-[3-(2-Benzotriazol-2-yl-4-chloro-phenoxy)-propoxy]-phenyl}-acetic acid and {4-[3-(2-benzotriazol-2-yl-4-thiophen-2-yl-phenoxy)-propoxy]-phenyl}-acetic acid | METABOLEX INC. (US) | 2009-11-24 | — | — | US | disclosed |
| EP-1776111-A2 | MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | METABOLEX, INC. (US) | 2007-04-25 | — | — | EP | disclosed |
| US-20060058301-A1 | Modulators of PPAR and methods of their preparation | METABOLEX, INC. (US) | 2006-03-16 | — | — | US | disclosed |
| WO-2006020916-A2 | MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | METABOLEX, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087468-A1 | MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | PPARG, PPARD, PPARA | PPARA 3/4885PPARG 1/4885LTB4R 2082/4885 |
| US-20060058301-A1 | Modulators of PPAR and methods of their preparation | PPARG, PPARD, PPARA | PPARA 3/4885PPARG 1/4885LTB4R 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.